Biogen Stays the Wrong Course After a Key Drug Failure

Apr 24 2019, 3:22 PMApr 24 2019, 4:45 PMApril 24 2019, 3:22 PMApril 24 2019, 4:45 PM

(Bloomberg Opinion) -- Biogen is by far the worst-performing large-cap biotech stock of 2019 after the March failure of its key Alzheimer’s drug pushed its shares down more than 20 percent. Its fi...